Embecta Corp. reported third-quarter fiscal 2026 results for the period ended June 30, 2026, announcing a quarterly cash dividend of $0.01 per share payable on September 15, 2026 to holders of record as of August 27, 2026. Reported revenues decreased 8.1% year-over-year to $271.7 million, driven by a 24.6% decline in U.S. sales, partially offset by an 11.5% increase in International revenue and contributions from the Owen Mumford acquisition. The company raised its full-year adjusted operating margin guidance to 23.50%-24.00% and adjusted EPS guidance to $1.80-$1.90, while reaffirming revenue guidance of $1.015 billion-$1.035 billion. Embecta operates in the diabetes care industry, manufacturing medical devices such as pen needles and syringes.

Embecta Corp. filed an amendment to its Form 8-K to provide the historical audited financial statements of Owen Mumford Holdings Limited and pro forma condensed consolidated financial information required by SEC regulations following the closing of the acquisition on May 15, 2026. The transaction involved an upfront cash payment of £126.0 million ($166.1 million) plus up to £50.0 million ($65.9 million) in performance-based earn-outs, totaling a maximum value of £176.0 million ($232.0 million). Owen Mumford reported turnover of £68.6 million and profit before tax of £1.9 million for the fiscal year ended September 30, 2025. Embecta Corp. operates in the medical device industry, specializing in drug delivery technologies.